Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 6 | Breast Cancer Research

Fig. 6

From: Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association

Fig. 6

SGRM treatment inhibits MCF-7 Y537S xenograft growth in vivo and is associated with decreased tumor CCND1 expression. MCF-7 HA-Y537S cells xenografted into SCID mice were treated 3 times weekly with 20 mg/kg C134 (134), 20 mg/kg C335 (335), or vehicle (Veh, 1 ETOH:9 sesame oil) for the duration of the study. a After 18 days of treatment with C134 or C335, there was significantly less tumor growth compared to vehicle-treated mice (*p < 0.05, one-way ANOVA, Tukey’s post hoc test, n = 6–8 per group, ±SD). Open circles represent tumors analyzed for CCND1 gene expression. b Median progression-free survival following vehicle, C134 or C335 was 18, 28, and 28 days, respectively (**p < 0.003, Log-rank (Mantel-Cox) test, n = 6–8 per group). c RNA was isolated from tumors, and CCND1 mRNA expression was measured. Compared to Veh-treated mice, CCND1 mRNA levels were significantly reduced following treatment with either C134 or C335 (*p < 0.05, **p < 0.01; vs. Veh, two-way ANOVA, Tukey’s post hoc test, n = 4–5 per group, ±SD). d MCF-7 HA-Y537S xenograft tumors were examined for Cyclin D1 IHC. Tumors from C335-treated mice had significantly lower Cyclin D1 IHC intensity compared to vehicle-treated mice (p = 0.0476, Fisher’s exact test, n = 5 per group). More C134-treated tumors (3/5) than vehicle (1/5) had low-intensity staining, but the difference did not reach statistical significance

Back to article page